DexCom — Third Quarter 2026 Earnings Summary

Dexcom reported third-quarter 2026 revenue of $1.344 billion, representing an 11% year-over-year increase on both a reported and organic basis. The company achieved GAAP operating income of $327.2 million, or 24.3% of revenue, while raising its full-year 2026 revenue guidance to a midpoint of $5.225 billion. Strategic milestones included the publication of the CONNECT clinical trial results in The New England Journal of Medicine and the launch of a redesigned Stelo experience. Additionally, Dexcom announced a new share repurchase authorization of up to $1.0 billion and holds $1.82 billion in cash and marketable securities as of September 30, 2026.